Columbia University
Irving Medical Center
Neurological Institute
710 West 168th Street, 3rd floor
(212) 305-1818
News
2024 - present | 2023 - 2011
November 1, 2024
By Linda Carroll and Mustafa Fattah
Columbia Neurologist Lawrence Honig, MD, PhD, commented on a recent single-center study that used a transcranial magnetic stimulation (TMS) device to target the key brain network that stores memories and is typically hit by Alzheimer’s Disease. This study is at an early stage. “The findings are very, very preliminary” said Dr. Honig “On the face of it, if you look at the numbers, it did better on a number of scales compared to the sham treatment — that’s good. But as in any study, the devil is in the details.” Dr, Honig noted that this is a small, single center study, and that “a multicenter trial would offer a little more hope of generalizability.” [read more]
Source: NBC News Online
October 29, 2024
Columbia Alzheimer's Specialist Lawrence S. Honig, MD, PhD speaks about the people who have received the new monoclonal antibody Alzheimer’s drugs as a third member of this family of drugs, donanemab, has become approved. Dr. Honig, like many neurologists, notes that these drugs clearly have clinical efficacy at slowing disease, but that there are uncertainties over the risks versus benefits and important details such as duration of treatment. While uncommon, there have been some deaths due to the side-effects of these drugs, including one person at Columbia who developed the brain swelling known as amyloid-related imaging abnormality (ARIA). [read more]
Source: Science
October 21, 2024
Davangere P. Devanand, MD, Professor of Psychiatry and Director of Geriatric Psychiatry at Columbia, and colleagues conducted a new study that used impairment in an odor identification test and global cognition to predict cognitive decline and dementia. "Our study highlights a practical and cost-effective approach for predicting cognitive decline and dementia, which could greatly improve access to early diagnosis," said Dr. Devanand. [read more]
Source: HealthDay News
October 18, 2024
Columbia Neurologist Philip L. De Jager, MD, PhD and Neuroscientist Vilas Menon, PhD led a technically complex and innovative study of Alzheimer’s Disease that, according to Dr. De Jager, “highlights that Alzheimer’s is a disease of many cells and their interactions, not just a single type of dysfunctional cell. We may need to modify cellular communities to preserve cognitive function, and our study reveals points along the sequence of events leading to Alzheimer’s where we may be able to intervene,” explains De Jager.
[read more]
Source: CUIMC Newsroom
August 30, 2024
A recent study led by Columbia Neurological Scientist Caghan Kizil, PhD showed how the ABCA7 gene, prevalent among Black Americans, leads to an increased risk of Alzheimer's disease. “Our findings not only enhance our understanding of Alzheimer’s, but they also provide a new direction for developing treatments that could halt or reverse the progression of the disease,” commented Dr. Kizil.
[read more]
Source: CUIMC Newsroom
Jul 7, 2024
Dr. Miguel Arce RenterĂa, a neuropsychologist at Columbia University, comments that treatment that focuses on social issues may hold off the worst of Alzheimer’s Disease for years.
[read more]
Source: The New York Times
Note: Accessing this article requires The New York Times subscription.
The European Medial Journal interviewed Yaakov Stern, PhD, Florence Irving Professor of Neuropsychology at Columbia University Irving Medical Center about his early career interests and the journey that led him to focus on conducting research on cognition and aging. Dr. Stern discusses the history of Alzheimer's disease research and how it has developed over the course of his career. The interview further offers current takeaways from his research, and what needs, challenges, and personal goals Dr. Stern aims to achieve in his work [read the interview]
Source: European Medial Journal
April 24, 2024
The CUIMC Healthy Aging Initiative (CHAI), with the support of the Four Deans Fund and the Robert N. Butler Columbia Aging Center, organized the Healthspan Extension Summit that focused on the rapidly growing aging population around the globe and the challenges that long lifespan presents. Researchers across various disciplines at CUIMC presented their ideas on what can be done to insure healthy quality of life for the aging world’s population.
Adam Brickman, PhD, Jennifer Manly, PhD, Scott Small, MD, from the Department of Neurology, presented their research findings and led panel discussions on age-related illness. [read more]
The APOEε4 gene variant is a major genetic risk factor for developing Alzheimer's disease (AD) later in life. People with two copies of this variant are almost certain to develop the disease, yet some people with this variant do not get dementia and scientists are still figuring out why. In a recent study, a team of investigators led by Drs. Badri Vardarajan, Caghan Kizil, and Richard Mayeux analyzed the genetic data of 3,500 individuals from over 700 families of different ethnic backgrounds. Their findings, published in Acta Neuropathologica and highlighted in the CUIMC Newsroom, revealed 510 genetic variants that might protect against AD. These protective variants mainly affect the genes involved with the brain's blood barrier system. Notably, one specific variant in the fibronectin (FN1) gene stood out. Research involving over 11,000 participants from Columbia, Stanford, and Washington universities showed that this FN1 variant can reduce the risk of AD by 71% and delay its onset by about four years. It does this by reducing the buildup of certain proteins and inflammation in the brain's blood vessels. Experiments with zebrafish and human brain studies after death showed that losing FN1 function helps clear harmful amyloid proteins and improves the activity of immune cells in the brain. This groundbreaking research opens up new possibilities for treating Alzheimer's disease by targeting the brain's blood vessels.
Associate Research Scientist Sharon Sanz Simon, PhD was interviewed for the Alzheimer's Association inaugural ISTAART Voices global podcasts about her work with Brazilian immigrants. Dr. Sanz Simon talked about the challenges this community faces, and discussed the need for more research on Alzheimer's disease and related dementias in this underrepresented population. One of the goals of her research is to develop more culturally sensitive intervention strategies for aging and dementia prevention in the Brazilian community living in the US. [listen to the podcast]
Rafael A. Lantigua, MD, Professor of Medicine and Dean's Special Advisor for Community Health Affairs at Columbia University Irving Medical Center, received the Presidential Volunteer Award from New York State Senator Luis SepĂşlveda. Dr. Lantigua was also honored with resolutions enacted in the New York State Senate and Assembly, which celebrated Dr. Lantigua's significant impact. [read more]
Source: CUIMC Newsroom
March 14, 2024
A healthier diet is associated with a reduced dementia risk and slower pace of aging, according to a new study at Columbia University Mailman School of Public Health and The Robert Butler Columbia Aging Center. The findings show that a diet-dementia association was at least partially facilitated by multi-system processes of aging. While literature had suggested that people who followed a healthy diet experienced a slowdown in the processes of biological aging and were less likely to develop dementia, until now the biological mechanism of this protection was not well understood. The results are published in the Annals of Neurology.
“We have some strong evidence that a healthy diet can protect against dementia,” said Yian Gu, PhD, associate professor of Neurological Sciences at Columbia Vagelos College of Physicians and Surgeons and head of the Mailman School Neuroepidemiology Unit, and the other senior author of the study, “But the mechanism of this protection is not well understood.” Past research linked both diet and dementia risk to an accelerated pace of biological aging. [read more]
Source: CUIMC Newsroom
February 7, 2024
Associate Professor of Neurology James Noble, MD, MS, along with nine other faculty members from Columbia University Irving Medical Center, was recently inducted into the Academy of Community and Public Service (ACPS) in recognition of his exceptional efforts to promote health, well-being, and overall quality of life in the local communities of upper Manhattan, as well as nationally and globally.
At the event, Professor of Neurology and Vice Dean of Community Health Dr. Olajide Williams, a co-chair of ACPS, said of the awardees, “The work and dedication to community and public service of the people here today are nothing short of inspiring. I’m a big believer in inspiration, because inspiration is what sparks imagination, and imagination sparks innovation. And it’s innovation that is truly going to move us to a place where we can finally say, ‘out of many, we are one.’” [read more]
Source: CUIMC Newsroom
February 7, 2024
5 Questions With Dr. James Noble
Dr. James Noble isn’t one for being boxed in. The neurologist and neuroepidemiologist at NewYork-Presbyterian/Columbia is an expert in dementia, but a sampling of his work reflects his broad clinical and research interests: He’s investigating the link between periodontal disease and Alzheimer’s disease. He’s developed a prototype for a device that helps diagnose concussions in real time. He’s researching how hip-hop can be used in health education and cofounded a nonprofit, Arts & Minds, to support the power of visual arts in improving wellness for dementia patients and caretakers.
These seemingly disparate projects all tie together for Dr. Noble. “First, I’m passionate about each of them. They tend to reflect a problem that I’m trying to solve or a question that I’m trying to answer,” he says. “And second, if I can prove in a methodical and scientifically rigorous way that all these things can make a difference for people, I believe they are worth doing.” [read more]
Source: NYP Advances
February 1, 2024
On January 23, 2024, Senior Staff Associate Danurys L. Sanchez and five other awardees were honored by Columbia University Vagelos College of Physicians and Surgeons (VP&S) with Martha A. Hooven Awards for Excellence. These awards are given annually to recognize individuals at VP&S who make significant contributions to the medical school’s workplace and community.
This year, Danurys (Didi) and her co-awardees were chosen from more than 160 nominations. This is the second time that Didi has received a Martha A. Hooven Award for Excellence, as mentioned by Dr. Olajide Williams, professor of neurology and vice dean of community health, who presented the award [watch the ceremony, with Didi's award beginning at 10:25.] “Didi understands cultural humanity; she understands mutual respect; she understands that the dedication to health justice is the only way to achieve strong recruitment and retention from our local community,” explains Dr. Williams.
In accepting the award, Didi was quick to credit the dedication of her team and colleagues, noting that she is “surrounded every day by people who are leaving their marks in this community…we are doing so much, and my deeds out there are a testament that I’m not by myself.”
The faculty and staff of the Department of Neurology, the Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, and the Gertrude H. Sergievsky Center congratulate Didi on this well-deserved honor!
Community Service AwardDanurys L. Sanchez is a senior staff associate for the Gertrude H. Sergievsky Center, where she collaborates with principal investigators to ensure the fulfillment of the center’s research mission. She has been a key team member for the Washington Heights-Inwood Columbia Aging Project since 2007, working to recruit participants, connect community members with relevant health care providers and social services, and increase community understanding of Alzheimer’s disease and related disorders. She also helps connect departments, faculty members, and researchers with community organizations, creating networks for all parties to collaborate and share resources.
January 18, 2024
By Gary Goldenberg
Over the years, zebrafish (and to a lesser extent killifish) have become an important experimental model in biomedical research, thanks to their genetic similarity to humans, transparent embryos, rapid development, and regenerative abilities, among other features. Columbia researchers are using these finned wonders to gain insights into human health and disease. Caghan Kizil, PhD, MSc, Associate Professor of Neurological Sciences in Neurology and in the Taub Institute, uses zebrafish in his research on Alzheimer's disease. [read more about how other Columbia researchers are using zebrafish in their work]
Can zebrafish teach us how to regenerate neurons?
No one would argue that zebrafish, whose brains are the size of a sesame seed, are smarter than humans. But these tiny aquatic animals can do a few tricks that humans cannot, such as growing scores of new brain neurons in response to neurological pathologies such as Alzheimer’s disease or injury, even well into adulthood. In contrast, once past childhood, humans can manage to regenerate only a smattering of neurons, a rate that declines even more with disease.
Using zebrafish as a model organism, Caghan Kizil, PhD, associate professor of neurological sciences (in neurology and in the Taub Institute) at the Vagelos College of Physicians and Surgeons, is gaining new insights into the molecular mechanisms that underlie neuronal regeneration, or neurogenesis.
“The beauty of zebrafish is that we can get human-relevant experimental results in weeks instead of months or years with other animal models,” adds Kizil. “We can even get these fish to perform memory tests to investigate the cognitive consequences of therapeutic interventions for neurological diseases.”
Thus far, Kizil’s studies have revealed a key molecule (nerve growth factor receptor) that controls nerve regeneration in zebrafish. The same molecule appears to be active in humans during early development but not in Alzheimer’s patients.
“If we could kickstart neurogenesis in humans, we might be able to slow the progression of Alzheimer’s by enhancing the brain’s resilience,” says Kizil. His team has already identified two potential targets for drug therapy. The researchers are designing compounds to selectively hit those targets, which they will evaluate in zebrafish.
Source: CUIMC Newsroom